<DOC>
	<DOCNO>NCT02261103</DOCNO>
	<brief_summary>The objective study : - To demonstrate similar total exposure pramipexole ER fast pramipexole ER fed multiple administration high daily dose 4.5 mg q.d . reveal food effect lead uncontrolled release - To investigate relative bioavailability ER-formulation pramipexole comparison IR-formulation high daily dose 4.5 mg multiple dose - To demonstrate dose proportionality dose strength pramipexole ER formulation 0.375 , 0.75 , 1.5 , 3.0 , 4.5 mg multiple daily ( q.d . ) dose</brief_summary>
	<brief_title>Bioavailability Increasing Pramipexole Doses Oral Extended Release ( ER ) Tablets Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pramipexole</mesh_term>
	<criteria>All participant study healthy male Age range 21 50 year Body mass index ( BMI ) within 18.5 29.9 kg/m2 In accordance Good Clinical Practice local legislation volunteer give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24:00 hour ) within least one month less ten halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment study study Participation another trial investigational drug ( ≤ one month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke inhouse trial day Alcohol abuse ( &gt; 40 g/day ) Drug abuse Blood donation ( ≥ 100 mL within four week prior administration trial ) Any laboratory value outside clinically accept reference range Excessive physical activity within last week trial trial Hypersensitivity pramipexole , dopamine agonist Supine blood pressure screen systolic &lt; 110 mmHg diastolic &lt; 60 mmHg</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>